000 01229 a2200349 4500
005 20250518090818.0
264 0 _c20210514
008 202105s 0 0 eng d
022 _a1365-2133
024 7 _a10.1111/bjd.19013
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aGisondi, P
245 0 0 _aSwitching from one infliximab biosimilar (CT-P13) to another infliximab biosimilar (SB2) in patients with chronic plaque psoriasis.
_h[electronic resource]
260 _bThe British journal of dermatology
_c08 2020
300 _a397-398 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAntibodies, Monoclonal
_xtherapeutic use
650 0 4 _aBiosimilar Pharmaceuticals
_xtherapeutic use
650 0 4 _aDrug Substitution
650 0 4 _aHumans
650 0 4 _aInfliximab
_xtherapeutic use
650 0 4 _aPsoriasis
_xdrug therapy
650 0 4 _aTreatment Outcome
700 1 _aVirga, C
700 1 _aPiaserico, S
700 1 _aMeneguzzo, A
700 1 _aOdorici, G
700 1 _aConti, A
700 1 _aGirolomoni, G
773 0 _tThe British journal of dermatology
_gvol. 183
_gno. 2
_gp. 397-398
856 4 0 _uhttps://doi.org/10.1111/bjd.19013
_zAvailable from publisher's website
999 _c30706869
_d30706869